Role of PET Imaging in Patients with High-Grade Gliomas undergoing anti-angiogenic Therapy with Bevacizumab – Review of the Literature and Case Report

Götz I; Grosu AL; Spehl TS

Götz I et al.

Role of PET Imaging in Patients with High-Grade Gliomas undergoing anti-angiogenic Therapy with Bevacizumab – Review of the Literature and Case Report

European Association of NeuroOncology Magazine 2014; 4 (3): 102-108

PDF Summary Figures

Figure

Maximize View	Glioblastoma Figure 1a-d: Imaging results of a patient with glioblastoma undergoing bevacizumab therapy. First column: MRI (MP-RAGE with contrast enhancement); second column: 18F-FET-PET (parametric images scaled to mean uptake in a right temporal reference region); third column: image fusion. (A) scan prior to therapy 07/2010; (B) scan after 8 weeks of bevacizumab 09/2010; (C) scan after 16 weeks of bevacizumab 11/2010; (D) scan after re-irradiation with 20 Gy, 01/2011. Bevacizumab therapy was continued. For details, see text Keywords: Bevacizumab, glioblastoma, MRI


Maximize View	Distant Tumour Figure 2a-c: (A) T1-weighted MRI, (B) parametric 18F-FET-PET, and (C) fused images of a distant tumour manifestation in the mesencephalon. Note that the Gd-enhancing lesion on the T1-weighted MRI is rather small and only visible on the left side, whereas the extent of 18F-FET uptake is much larger and extends to the right side. Keywords: MRI, tumour